Cobo is a leading producer of hardware and software blockchain products that make it easy for anyone to own and use cryptocurrencies.. Currently, Cobo offers both an innovative software wallet and the world’s first military-grade cryptocurrency cold storage wallet. Cobo’s flagship software wallet, Cobo Wallet, is the first mobile wallet to offer a proof-of-stake pooling service, a groundbreaking feature that allows users to generate benefits from their cryptocurrency holdings. To date, Cobo Wallet has registered more than 500,000 users globally and supports up to 30 cryptocurrencies and 500 tokens on mainchains including ETH, EOS and TRX. Cobo Vault is the world’s first military grade cryptocurrency cold storage wallet designed to protect cryptocurrency from digital hacking attempts, hardware tampering, and from physical damage. Offering multiple levels of security, Cobo Vault was designed and built with prevention in mind. Founded in November 2017 by former Facebook engineer, Changhao Jiang, and founder of F2Pool, Discus Fish, Cobo is headquartered in Beijing, with offices in Shanghai, Xi'an, and Seattle. For more information about Cobo, visit http://cobo.com
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.
PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. Beam is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Founded in 2018 by professors of Yale University and Columbia University, CertiK is a pioneer in blockchain security, utilizing best-in-class AI technology to secure and monitor blockchain protocols and smart contracts. CertiK’s mission is to secure the cyber world. Starting with blockchain, CertiK applies cutting-edge innovations from academia into enterprise, enabling mission-critical applications to be built with security and correctness.
Viz helps physicians to identify anomalies in brain scans through machine learning. The company leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. It uses deep learning algorithms to identify a suspected large vessel occlusion, a particularly disabling type of stroke, in a CT scan and alerts the stroke team specialist within minutes. Viz has developed deep learning algorithms to analyze brain scans for large vessel occlusions (LVOs), a disabling type of stroke. The company also allows the stroke center’s clinicians to rapidly share images back and forth. Viz's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz was founded in 2016 and is based in San Francisco, California.
Founded in 2018 with offices across three countries and two continents, InfStones is the world's leading blockchain infrastructure provider. Currently, InfStones provides services to large institutional clients around the globe, supporting thousands of nodes on more than 50 public blockchains through its universal platform.
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber. Mammoth has also been working on developing a rapid COVID-19 test.
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery. Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications.
The DFINITY Foundation is a not-for-profit organization based in Zurich, Switzerland. Our mission is to build, promote, and maintain the Internet Computer — and by doing so, improve the world. The Internet Computer extends the functionality of the internet from connecting billions of people to providing millions of developers and entrepreneurs with a public compute platform — creating a revolutionary new way to build websites, enterprise systems and internet services within an open environment. This public software development platform is created by independent data centers around the world combining computing power using an advanced decentralized protocol called ICP. In turn, this generational shift in computing aims to take on Big Tech and return the internet back to its free and open roots. DFINITY was founded in 2016 by Dominic Williams.